{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:09:32Z","timestamp":1756894172471,"version":"3.41.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.neuropharm.2016.12.004","type":"journal-article","created":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T01:42:13Z","timestamp":1481334133000},"page":"38-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Diverse arrestin-recruiting and endocytic profiles of tricyclic antipsychotics acting as direct \u03b1 2A adrenergic receptor ligands"],"prefix":"10.1016","volume":"116","author":[{"given":"Christopher","family":"Cottingham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pulin","family":"Che","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond X.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Percival","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tana","family":"Birky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lufang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2016.12.004_bib1","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nrn2059","article-title":"Lipid raft microdomains and neurotransmitter signalling","volume":"8","author":"Allen","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib2","series-title":"Goodman & Gilman's the Pharmacological Basis of Therapeutics","first-page":"429","article-title":"Drug therapy of depression and anxiety disorders","author":"Baldessarini","year":"2006"},{"key":"10.1016\/j.neuropharm.2016.12.004_bib3","series-title":"Goodman & Gilman's the Pharmacological Basis of Therapeutics","article-title":"Pharmacotherapy of psychosis and mania","author":"Baldessarini","year":"2006"},{"key":"10.1016\/j.neuropharm.2016.12.004_bib4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1043-9471(05)80049-7","article-title":"Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors","volume":"25","author":"Ballesteros","year":"1995","journal-title":"Methods Neurosci."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib5","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.lfs.2005.05.040","article-title":"Lipids, lipid rafts and caveolae: their importance for GPCR signaling and their centrality to the endocannabinoid system","volume":"77","author":"Barnett-Norris","year":"2005","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib6","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1124\/mol.104.005215","article-title":"Alpha 2-adrenergic agonist enrichment of spinophilin at the cell surface involves beta gamma subunits of Gi proteins and is preferentially induced by the alpha 2A-subtype","volume":"67","author":"Brady","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib7","doi-asserted-by":"crossref","first-page":"32405","DOI":"10.1074\/jbc.M304195200","article-title":"Spinophilin stabilizes cell surface expression of alpha 2B-adrenergic receptors","volume":"278","author":"Brady","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib8","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1523\/JNEUROSCI.4125-11.2011","article-title":"Neurabin scaffolding of adenosine receptor and RGS4 regulates anti-seizure effect of endogenous adenosine","volume":"32","author":"Chen","year":"2012","journal-title":"J.\u00a0Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib9","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1677\/jme.0.0320325","article-title":"G-protein coupled receptors in lipid rafts and caveolae: how, when and why do they go there?","volume":"32","author":"Chini","year":"2004","journal-title":"J.\u00a0Mol. Endocrinol."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0026-895X(25)13852-2","article-title":"Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition","volume":"10","author":"Chou","year":"1974","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.tips.2014.04.004","article-title":"Modeling G protein-coupled receptors in complex with biased agonists","volume":"35","author":"Costanzi","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib13","doi-asserted-by":"crossref","first-page":"36063","DOI":"10.1074\/jbc.M111.261578","article-title":"The antidepressant desipramine is an arrestin-biased ligand at the alpha(2A)-adrenergic receptor driving receptor down-regulation in\u00a0vitro and in\u00a0vivo","volume":"286","author":"Cottingham","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbrc.2012.02.135","article-title":"Desipramine selectively potentiates norepinephrine-elicited ERK1\/2 activation through the alpha2A adrenergic receptor","volume":"420","author":"Cottingham","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib15","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1016\/j.neuropharm.2012.02.011","article-title":"Noradrenergic antidepressant responses to desipramine in\u00a0vivo are reciprocally regulated by arrestin3 and spinophilin","volume":"62","author":"Cottingham","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.12.004_bib16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.bbrc.2014.08.024","article-title":"Tricyclic antidepressants exhibit variable pharmacological profiles at the \u03b12A adrenergic receptor","volume":"451","author":"Cottingham","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib17","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.neubiorev.2012.07.011","article-title":"\u03b12 adrenergic receptor dysregulation in depressive disorders: implications for the neurobiology of depression and antidepressant therapy","volume":"36","author":"Cottingham","year":"2012","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib18","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/j.1471-4159.1992.tb11378.x","article-title":"Regional distribution of alpha 2A- and alpha 2B-adrenoceptor subtypes in postmortem human brain","volume":"58","author":"De Vos","year":"1992","journal-title":"JNeurochem"},{"year":"2014","series-title":"Glide, Version 6.3","key":"10.1016\/j.neuropharm.2016.12.004_bib19"},{"key":"10.1016\/j.neuropharm.2016.12.004_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1083\/jcb.121.1.61","article-title":"Clathrin and HA2 adaptors: effects of potassium depletion, hypertonic medium, and cytosol acidification","volume":"121","author":"Hansen","year":"1993","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib21","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1146\/annurev.pharmtox.48.113006.094830","article-title":"Regulation of GPCRs by endocytic membrane trafficking and its potential implications","volume":"48","author":"Hanyaloglu","year":"2008","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ceb.2015.05.005","article-title":"Effects of endocytosis on receptor-mediated signaling","volume":"35","author":"Irannejad","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.tips.2011.02.005","article-title":"Structural insights into adrenergic receptor function and pharmacology","volume":"32","author":"Kobilka","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nature10136","article-title":"Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation","volume":"474","author":"Lebon","year":"2011","journal-title":"Nature"},{"year":"2009","series-title":"LigPrep, Version 2.3","key":"10.1016\/j.neuropharm.2016.12.004_bib25"},{"year":"2005","series-title":"Cell Surface Receptors: a Short Course on Theory and Methods","author":"Limbird","key":"10.1016\/j.neuropharm.2016.12.004_bib26"},{"key":"10.1016\/j.neuropharm.2016.12.004_bib27","doi-asserted-by":"crossref","first-page":"13233","DOI":"10.1074\/jbc.M807535200","article-title":"Epitope-tagged receptor knock-in mice reveal that differential desensitization of alpha2-adrenergic responses is because of ligand-selective internalization","volume":"284","author":"Lu","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib28","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.273.5276.801","article-title":"Central hypotensive effects of the alpha2a-adrenergic receptor subtype","volume":"273","author":"MacMillan","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2016.12.004_bib29","series-title":"Goodman & Gilman's the Pharmacological Basis of Therapeutics","article-title":"Pharmacotherapy of psychosis and mania","author":"Meyer","year":"2011"},{"key":"10.1016\/j.neuropharm.2016.12.004_bib30","series-title":"Goodman & Gilman's the Pharmacological Basis of Therapeutics, Online Edition","article-title":"Neurotransmission and the central nervous system","author":"Molinoff","year":"2011"},{"year":"2007","series-title":"Prime, Version 1.6","key":"10.1016\/j.neuropharm.2016.12.004_bib31"},{"key":"10.1016\/j.neuropharm.2016.12.004_bib32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrd3024","article-title":"Teaching old receptors new tricks: biasing seven-transmembrane receptors","volume":"9","author":"Rajagopal","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib33","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nature12572","article-title":"Adrenaline-activated structure of \u03b22-adrenoceptor stabilized by an engineered nanobody","volume":"502","author":"Ring","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2016.12.004_bib34","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1046\/j.1471-4159.1994.63031077.x","article-title":"Alpha 2-adrenoceptor subtypes identified by [3H]RX821002 binding in the human brain: the agonist guanoxabenz does not discriminate different forms of the predominant alpha 2A subtype","volume":"63","author":"Sastre","year":"1994","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib35","doi-asserted-by":"crossref","first-page":"24935","DOI":"10.1074\/jbc.274.35.24935","article-title":"Stimulation of mitogen-activated protein kinase by G protein-coupled alpha(2)-adrenergic receptors does not require agonist-elicited endocytosis","volume":"274","author":"Schramm","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib36","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm050540c","article-title":"Novel procedure for modeling ligand\/receptor induced fit effects","volume":"49","author":"Sherman","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib37","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.tips.2012.03.007","article-title":"Structure-based drug screening for G-protein-coupled receptors","volume":"33","author":"Shoichet","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib38","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1146\/annurev.pharmtox.44.101802.121558","article-title":"Membrane trafficking of G protein-coupled receptors","volume":"44","author":"Tan","year":"2004","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib39","doi-asserted-by":"crossref","first-page":"12471","DOI":"10.1073\/pnas.122368499","article-title":"Heterozygous alpha 2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists","volume":"99","author":"Tan","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib40","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.tips.2007.06.006","article-title":"Beta-arrestin-biased ligands at seven-transmembrane receptors","volume":"28","author":"Violin","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neuron.2012.09.022","article-title":"Modulating neuromodulation by receptor membrane traffic in the endocytic pathway","volume":"76","author":"von Zastrow","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2016.12.004_bib42","doi-asserted-by":"crossref","first-page":"25948","DOI":"10.1074\/jbc.M605415200","article-title":"Arrestin serves as a molecular switch, linking endogenous alpha2-adrenergic receptor to SRC-dependent, but not SRC-independent, ERK activation","volume":"281","author":"Wang","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib43","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1126\/science.1098274","article-title":"Spinophilin blocks arrestin actions in\u00a0vitro and in\u00a0vivo at G protein-coupled receptors","volume":"304","author":"Wang","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2016.12.004_bib44","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0306-4522(96)00116-9","article-title":"Expression of alpha 2-adrenergic receptor subtypes in the mouse brain: evaluation of spatial and temporal information imparted by 3 kb of 5\u2019 regulatory sequence for the alpha 2A AR-receptor gene in transgenic animals","volume":"74","author":"Wang","year":"1996","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2016.12.004_bib45","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nature09746","article-title":"The structural basis for agonist and partial agonist action on a \u03b2(1)-adrenergic receptor","volume":"469","author":"Warne","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2016.12.004_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2015.00197","article-title":"A\u00a0role for fragment-based drug design in developing novel lead compounds for central nervous system targets","volume":"6","author":"Wasko","year":"2015","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2016.12.004_bib47","doi-asserted-by":"crossref","first-page":"14516","DOI":"10.1074\/jbc.M710340200","article-title":"Protein kinase A phosphorylation of spinophilin modulates its interaction with the alpha 2A-adrenergic receptor (AR) and alters temporal properties of alpha 2AAR internalization","volume":"283","author":"Xu","year":"2008","journal-title":"J.\u00a0Biol. Chem."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390816305597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390816305597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T12:11:28Z","timestamp":1749816688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390816305597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":47,"alternative-id":["S0028390816305597"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.12.004","relation":{},"ISSN":["0028-3908"],"issn-type":[{"type":"print","value":"0028-3908"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diverse arrestin-recruiting and endocytic profiles of tricyclic antipsychotics acting as direct \u03b12A adrenergic receptor ligands","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}